<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37781365</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>High CD8<sup>+</sup>tumor-infiltrating lymphocytes indicate severe exhaustion and poor prognosis in angioimmunoblastic T-cell lymphoma.</ArticleTitle><Pagination><StartPage>1228004</StartPage><MedlinePgn>1228004</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1228004</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1228004</ELocationID><Abstract><AbstractText Label="BACKGROUND">Exhaustion of CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs), characterized by the overexpression of immune checkpoints (IC), is a major impediment to anti-tumor immunity. However, the exhaustion status of CD8<sup>+</sup>TILs in angioimmunoblastic T cell lymphoma (AITL) remains unclear. Therefore, we aimed to elucidate the exhaustion status of CD8<sup>+</sup>TILs in AITL and its influence on prognosis.</AbstractText><AbstractText Label="METHODS">The correlation between CD8<sup>+</sup>TILs and IC expression in AITL was analyzed using single-cell RNA sequencing (n = 2), flow cytometry (n = 20), and RNA sequencing (n = 20). Biological changes related to CD8<sup>+</sup>TILs exhaustion at different cytotoxic T lymphocyte (CTL) levels (mean expression levels of CD8A, CD8B, GZMA, GZMB, and PRF1) in AITL were evaluated using RNA sequencing (n = 20) and further validated using the GEO dataset (n = 51). The impact of CD8 protein expression and CTL levels on patient prognosis was analyzed using flow cytometry and RNA sequencing, respectively.</AbstractText><AbstractText Label="RESULTS">Our findings demonstrated that the higher the infiltration of CD8<sup>+</sup>TILs, the higher was the proportion of exhausted CD8<sup>+</sup>TILs characterized by the overexpression of multiple IC. This was accompanied by extensive exhaustion-related biological changes, which suggested severe exhaustion in CD8<sup>+</sup>TILs and may be one of the main reasons for the poor prognosis of patients with high CD8<sup>+</sup>TILs and CTL.</AbstractText><AbstractText Label="CONCLUSION">Our study comprehensively reveals the exhaustion status of CD8<sup>+</sup>TILs and their potential negative impact on AITL prognosis, which facilitates further mechanistic studies and is valuable for guiding immunotherapy strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zhu, Yang, Deng, Chao, Chen, Ye, Zhang, Liu and Zhao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qiqi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, North Sichuan Medical College, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, North Sichuan Medical College, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xueqin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Ningning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zihang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Weiping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Sha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016246" MajorTopicYN="Y">Lymphocytes, Tumor-Infiltrating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016399" MajorTopicYN="Y">Lymphoma, T-Cell</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD8 + tumor-infiltrating lymphocytes</Keyword><Keyword MajorTopicYN="N">angioimmunoblastic T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">exhaustion</Keyword><Keyword MajorTopicYN="N">immune checkpoint</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">single-cell RNA sequencing</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37781365</ArticleId><ArticleId IdType="pmc">PMC10540231</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1228004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia (2020) 34(10):2592&#x2013;606. doi:&#xa0;10.1038/s41375-020-0990-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0990-y</ArticleId><ArticleId IdType="pmc">PMC7376827</ArticleId><ArticleId IdType="pubmed">32704161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood (2017) 129(9):1095&#x2013;102. doi:&#xa0;10.1182/blood-2016-09-692541</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-692541</ArticleId><ArticleId IdType="pubmed">28115369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Deng X, Yao W, Chen Z, Ye Y, Gao L, et al. . Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma. Ann Hematol (2021) 100(3):715&#x2013;23. doi:&#xa0;10.1007/s00277-020-04389-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04389-5</ArticleId><ArticleId IdType="pubmed">33389024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Zhu Q, Deng X, Yao W, Zhang W, Liu W, et al. . Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment. Front Immunol (2022) 13987227:987227. doi:&#xa0;10.3389/fimmu.2022.987227</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.987227</ArticleId><ArticleId IdType="pmc">PMC9618886</ArticleId><ArticleId IdType="pubmed">36325319</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueguen P, Metoikidou C, Dupic T, Lawand M, Goudot C, Baulande S, et al. . Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer. Sci Immunol (2021) 6(55):eabd5778. doi:&#xa0;10.1126/sciimmunol.abd5778</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd5778</ArticleId><ArticleId IdType="pubmed">33514641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong SA, Hwang HW, Kim MK, Lee TJ, Yim K, Won HS, et al. . High endothelial venule with concomitant high CD8+ Tumor-infiltrating lymphocytes is associated with a favorable prognosis in resected gastric cancer. J Clin Med (2020) 9(8):2628. doi:&#xa0;10.3390/jcm9082628</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082628</ArticleId><ArticleId IdType="pmc">PMC7464373</ArticleId><ArticleId IdType="pubmed">32823631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Deng X, Ye Y, Gao L, Zhang W, Liu W, et al. . Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry. Ann Hematol (2019) 98(2):391&#x2013;9. doi:&#xa0;10.1007/s00277-018-3534-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-018-3534-z</ArticleId><ArticleId IdType="pubmed">30377764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med (2018) 24(10):1550&#x2013;8. doi:&#xa0;10.1038/s41591-018-0136-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0136-1</ArticleId><ArticleId IdType="pmc">PMC6487502</ArticleId><ArticleId IdType="pubmed">30127393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. . Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 27(4):670&#x2013;84. doi:&#xa0;10.1016/j.immuni.2007.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.09.006</ArticleId><ArticleId IdType="pubmed">17950003</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano M, Henin C, Maurizio J, Imbratta C, Bourdely P, Buferne M, et al. . Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J (2015) 34(15):2042&#x2013;58. doi:&#xa0;10.15252/embj.201490786</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201490786</ArticleId><ArticleId IdType="pmc">PMC4551351</ArticleId><ArticleId IdType="pubmed">26139534</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Xu J, Wu X, Yao H, Yan Z, Guo T, et al. . CD147 regulates antitumor CD8(+) T-cell responses to facilitate tumor-immune escape. Cell Mol Immunol (2021) 18(8):1995&#x2013;2009. doi:&#xa0;10.1038/s41423-020-00570-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00570-y</ArticleId><ArticleId IdType="pmc">PMC8322173</ArticleId><ArticleId IdType="pubmed">33177695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8(+) T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today (2021) 26(4):951&#x2013;67. doi:&#xa0;10.1016/j.drudis.2021.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2021.01.002</ArticleId><ArticleId IdType="pmc">PMC8131230</ArticleId><ArticleId IdType="pubmed">33450394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Attwood K, Bshara W, Mohler JL, Guru K, Xu B, et al. . High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate (2021) 81(1):20&#x2013;8. doi:&#xa0;10.1002/pros.24068</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.24068</ArticleId><ArticleId IdType="pmc">PMC9869431</ArticleId><ArticleId IdType="pubmed">33085799</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol (2019) 234(6):8509&#x2013;21. doi:&#xa0;10.1002/jcp.27782</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27782</ArticleId><ArticleId IdType="pubmed">30520029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Green M, Choi JE, Gij&#xf3;n M, Kennedy PD, Johnson JK, et al. . CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature (2019) 569(7755):270&#x2013;4. doi:&#xa0;10.1038/s41586-019-1170-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId><ArticleId IdType="pmc">PMC6533917</ArticleId><ArticleId IdType="pubmed">31043744</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. . Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell (2019) 35(6):885&#x2013;900.e810. doi:&#xa0;10.1016/j.ccell.2019.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2019.05.004</ArticleId><ArticleId IdType="pmc">PMC6961655</ArticleId><ArticleId IdType="pubmed">31185212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Musa AE. Boosting immune system against cancer by resveratrol. Phytother Res: PTR (2021) 35(10):5514&#x2013;26. doi:&#xa0;10.1002/ptr.7189</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7189</ArticleId><ArticleId IdType="pubmed">34101276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchett JC, Yang ZZ, Kim HJ, Villasboas JC, Tang X, Jalali S, et al. . High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia (2022) 36(1):165&#x2013;76. doi:&#xa0;10.1038/s41375-021-01321-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01321-2</ArticleId><ArticleId IdType="pubmed">34230608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandu I, Cerletti D, Claassen M, Oxenius A. Exhausted CD8(+) T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection. Nat Commun (2020) 11(1):4454. doi:&#xa0;10.1038/s41467-020-18256-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18256-4</ArticleId><ArticleId IdType="pmc">PMC7479152</ArticleId><ArticleId IdType="pubmed">32901001</ArticleId></ArticleIdList></Reference><Reference><Citation>McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol (2019) 37:457&#x2013;95. doi:&#xa0;10.1146/annurev-immunol-041015-055318</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055318</ArticleId><ArticleId IdType="pubmed">30676822</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, et al. . Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol (2020), 11622509. doi:&#xa0;10.3389/fimmu.2020.622509</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.622509</ArticleId><ArticleId IdType="pmc">PMC7902023</ArticleId><ArticleId IdType="pubmed">33633741</ArticleId></ArticleIdList></Reference><Reference><Citation>Awwad MHS, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R, et al. . Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia (2021) 35(9):2602&#x2013;15. doi:&#xa0;10.1038/s41375-021-01172-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01172-x</ArticleId><ArticleId IdType="pmc">PMC8410603</ArticleId><ArticleId IdType="pubmed">33597728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. . Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol (2019) 20(6):724&#x2013;35. doi:&#xa0;10.1038/s41590-019-0346-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0346-9</ArticleId><ArticleId IdType="pmc">PMC6531353</ArticleId><ArticleId IdType="pubmed">30936494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12(6):492&#x2013;9. doi:&#xa0;10.1038/ni.2035</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2035</ArticleId><ArticleId IdType="pubmed">21739672</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connell P, Hyslop S, Blake MK, Godbehere S, Amalfitano A, Aldhamen YA. SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment. J Immunol (Baltimore Md: 1950) (2021) 206(1):193&#x2013;205. doi:&#xa0;10.4049/jimmunol.2000300</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000300</ArticleId><ArticleId IdType="pmc">PMC7855551</ArticleId><ArticleId IdType="pubmed">33288545</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, et al. . Endogenous glucocorticoid signaling regulates CD8(+) T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity (2020) 53(3):658&#x2013;671.e656. doi:&#xa0;10.1016/j.immuni.2020.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.08.005</ArticleId><ArticleId IdType="pmc">PMC7682805</ArticleId><ArticleId IdType="pubmed">32937153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, et al. . Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Res Rev (2021) 41(1):156&#x2013;201. doi:&#xa0;10.1002/med.21727</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21727</ArticleId><ArticleId IdType="pubmed">32844499</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YR, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, et al. . Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion. Nat Immunol (2020) 21(12):1540&#x2013;51. doi:&#xa0;10.1038/s41590-020-0793-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0793-3</ArticleId><ArticleId IdType="pubmed">33020660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Latorre-Muro P, Puigserver P. Mechanisms of mitochondrial respiratory adaptation. Nat Rev Mol Cell Biol (2022) 23(12):817&#x2013;35. doi:&#xa0;10.1038/s41580-022-00506-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-022-00506-6</ArticleId><ArticleId IdType="pmc">PMC9926497</ArticleId><ArticleId IdType="pubmed">35804199</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, et al. . Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci USA (2017) 114(29):E5900&#x2013;e5909. doi:&#xa0;10.1073/pnas.1706559114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1706559114</ArticleId><ArticleId IdType="pmc">PMC5530700</ArticleId><ArticleId IdType="pubmed">28674001</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, et al. . Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell (2015) 163(1):160&#x2013;73. doi:&#xa0;10.1016/j.cell.2015.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.001</ArticleId><ArticleId IdType="pmc">PMC4597190</ArticleId><ArticleId IdType="pubmed">26406376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurachi M. CD8(+) T cell exhaustion. Semin Immunopathol (2019) 41(3):327&#x2013;37. doi:&#xa0;10.1007/s00281-019-00744-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-019-00744-5</ArticleId><ArticleId IdType="pubmed">30989321</ArticleId></ArticleIdList></Reference><Reference><Citation>Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer (2019) 7(1):175. doi:&#xa0;10.1186/s40425-019-0611-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-019-0611-3</ArticleId><ArticleId IdType="pmc">PMC6621946</ArticleId><ArticleId IdType="pubmed">31291985</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuch S, Laskus T, Berak H, Perlejewski K, Metzner KJ, Paciorek M, et al. . Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. Sci Rep (2020) 10(1):16060. doi:&#xa0;10.1038/s41598-020-73137-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73137-6</ArticleId><ArticleId IdType="pmc">PMC7524731</ArticleId><ArticleId IdType="pubmed">32994477</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>